Chair of Sernova Biotherapeutics Resigns

Rhea-AI Summary

Sernova Biotherapeutics (SEOVF), a regenerative medicine company developing Cell Pouch Bio-hybrid Organ for type 1 diabetes treatment, announced the resignation of its Board Chair, Ross Haghighat. The resignation was tendered on May 24th, 2025, and accepted by Sernova's Board of Directors. The company expressed gratitude for Haghighat's leadership and extended well wishes for his future endeavors.

Positive

• None.

Negative

• Unexpected departure of Board Chair could create leadership uncertainty
• Timing and immediate acceptance of resignation might suggest potential internal challenges

LONDON, Ontario and BOSTON, May 26, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced the resignation of its Chair.

Mr. Ross Haghighat tendered his resignation on May 24^th and it was accepted by the Sernova Board. The Board of Directors of Sernova thanks Ross for his service as a trusted leader and sincerely wishes him luck in the future.

ABOUT SERNOVA BIOTHERAPEUTICS

Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem-cell derived islet like clusters in collaboration with Evotec to create Bio-hybrid Organs to treat T1D. A Bio-hybrid Organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on T1D and thyroid disorders.

FOR FURTHER INFORMATION, PLEASE CONTACT:

David Burke VP, Investor Relations (917) 751-5713 Email: David.Burke@sernova.com Website: https://sernova.com/

The TSX has not reviewed this news release and does not accept responsibility for the accuracy or adequacy of this news release.

FAQ

Who resigned as Chair of Sernova Biotherapeutics (SEOVF) in May 2025?

Ross Haghighat resigned as Chair of Sernova Biotherapeutics, with his resignation being tendered on May 24th, 2025.

What is Sernova Biotherapeutics' (SEOVF) main product focus?

Sernova Biotherapeutics is developing a Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D).

When did Ross Haghighat's resignation from Sernova become effective?

Ross Haghighat tendered his resignation on May 24th, 2025, and it was immediately accepted by Sernova's Board of Directors.

What stock exchanges is Sernova Biotherapeutics listed on?

Sernova Biotherapeutics is listed on the Toronto Stock Exchange (TSX: SVA), OTCQB (SEOVF), and Frankfurt Stock Exchange (FSE/XETRA: PSH).